Neurocrine Biosciences (NBIX) stock

Neurological medicines , market cap $16B

Neurological medicines

Worth $16B

$164.63

+3.05%

As of 9:10 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Above Average

In its industry

#23of 281

Biotech

Checks firing

4of 14

Trending up

From 52-week high

-11.5%

under its best in a year

NBIX's Quality Score rose 3 points on Fri, Nov 6, to 14. Its price is above its average prices of the last 8, 21, 50, and 200 days, which line up in that order (3 chart checks started).

Follow NBIX's trial news. Pro members can get an alert when Neurocrine Biosciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NBIX files news on its trialsSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is NBIX up?

Up 13.4% on Nov 3, and still 13% over its Nov 2 close.

Its Nov 2 results: total revenues were $1.12B, from $795M a year before; INGREZZA Net Product Sales were $801M, from $687M. It rose 13% on Nov 3.

Sources: Price history, Nov 3, 2026; Company release, Nov 2, 2026

1 more reason, free with an account →1 more reason why NBIX rose on Nov 3, from its filings, with the other side, the timeline, and its peers, for Pro members.

Key facts on NBIX

Key facts on NBIX
The company	Sales up 38% on the year
Latest filing	8-K, Nov 2 Reported its quarterly results

1 more reason behind NBIX's 14, free with an account →3 more reasons behind NBIX's 14, for Pro members.

NBIX in the news

Wed Nov 4Neurocrine Biosciences director George Morrow sells $2.3M in stock By Investing.com investing.com india and 3 more · yesterday 6:44 PM ET NBIX closed +0.7% that day.

NBIX catalysts

Coming up

After its last 4 reports it closed +0.4% on average, higher 2 of 4 times.

4 more coming up and 36 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for NBIX

Its trials

A trial underway: Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive DisorderPhase 3 · Recruiting · 200 people · main data estimated Jul 2027 · NCT06786624

17 more trials, 30 filings, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

Director George J. Morrow sold 15,000 shares on Nov 3, under a planned sale. 19 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Kyle Gano buys or sells

For Pro members: every trade, and Kyle Gano’s 11 filings and quotes.

Get an alert when NBIX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why NBIX scores 14

Above Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. NBIX scores 14 today, against a median of 8.5 over its last 20 recorded sessions.

+4Chart checks 4 of 14 firing right now, one point each
+3Growth sales up 38% on the year, operating margin up 3.5 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

Long-term trend adds
Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
News adds

No effect today: Run-up, Dilution, Volatility, Cash flow, and Persistence.

What every line is worth, and the reason behind it, on NBIX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:10 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when NBIX's Quality Score turns up

A free account. No card.

How NBIX ranks in Biotech

NBIX is #23 of 281 by Quality Score.

How NBIX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	NAGENiagen Bioscience		Open for its score
	NAMSNewAmsterdam Pharma		Open for its score
	NGENNervGen Pharma		Open for its score
	NGNENeurogene		Open for its score
23	NBIXNeurocrine Biosciences	4/14	14

Net income over four quarters: NBIX $702M, RGEN $41.5M, TARS -$46.5M, RVMD -$1.87B.

When does NBIX report earnings, and what happens after?

Expected to report Thu Feb 11, after the close (in 94 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What NBIX reported on Nov 2, 2026

The quarter

Sales of $1.1B, 41% more than a year ago; a profit of $1.96 a share, from $2.04.

“Our third quarter performance marks another important milestone in Neurocrine’s evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Productup 42%	$1.1B99%	$954M99%	$790M99%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 2)

1 more line, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
INGREZZA net product sales	$2.900B to $2.925Braised

Figures as filed (SEC filing, Nov 2)

In the company's words

“CRENESSITY third-quarter 2026 net product sales were $211 million, driven by steady new patient demand and high rates of persistency with approximately 80% reimbursement for dispensed prescriptions.”

From its results filing (SEC filing · Nov 2)

1 more sentence, for Pro members.

The numbers

Market value: $16B; today
Sales: $3.7B; up 38% on the year
Free cash flow: $1B; last 12 months

Sales grew 22% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 0.9% a year over 5 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on NBIX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+8.9%-10.1%+13.4%

May 5Jul 30Nov 2

Reported	When	Gap	Reaction	5 days
Nov 2, 2026After close	After close	+9.4%	+13.4%	not yet
Jul 30, 2026After close	After close	-0.6%	-10.1%	-13.8%
May 5, 2026After close	After close	+10.3%	+8.9%	+15.4%

NBIX closed higher after 2 of its last 4 reports.

All 4 reports, and NBIX's Quality Score going into each

NBIX sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $2.9B. It made a profit in each of the eight years.

NBIX has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on NBIX, and all 14 on every stock.Get in free →

NBIX RSI on Nov 6: 69.4, above its 50-day and 200-day averages

Not scored

RSI 69.4, MACD above signal, above both averages. Not scored.13 readings

The deep dive on NBIX

What it does and how it makes money3 findingsIt kept 22 cents of each dollar of sales in fiscal 2025: $619M of operating profit on $2.86B of sales.Annual report, filed Feb 11, 2026"INGREZZA, our highly selective VMAT2 inhibitor approved in the U.S. for the treatment of TD and of chorea associated with Huntington’s disease, is covered by 22 issued, FDA Orange Book-listed U.S. patents which are set to expire between 2027 and 2040." (10-K for fiscal 2025)SEC filing · Feb 11, 2026
Where it stands2 findingsFor Pro members2 findings on where NBIX stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findings"We filed suit in the U.S. District Court for the District of Delaware in October 2026 against Alvogen." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 2, 2026A new heading in its "Risk Factors" this year: "International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 11, 2026, against the one of Feb 10, 2025One customer made up 39% of its revenue in fiscal 2025, down from 43% in fiscal 2024; another made up 19%, up from 13% in fiscal 2024.SEC filing · Feb 11, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades NBIX, for Pro members
Against its closest peers4 peersNet income over four quarters: NBIX $702M, RGEN $41.5M, TARS -$46.5M, RVMD -$1.87B.

7 more findings on NBIX, each with its source, for Pro members.

NBIX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Kyle GanoChief Executive Officer · 1 trade
Matt AbernethyChief Financial Officer · 1 trade
Ingrid DelaetChief Regulatory Officer · 5 trades
Darin LippoldtChief Legal Officer · 4 trades
David W. BoyerChief Corp. Affairs Officer · 2 trades
Eric BenevichChief Commercial Officer · 2 trades
Jude OnyiaChief Scientific Officer · 2 trades
Julie CookeChief Human Resources Officer · 1 trade

11 more officers and directors file at NBIX.

See insider trades by person

Which ETFs hold NBIX?

In ETFs: NBIX is under 0.1% of SCHG and under 0.1% of VTI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.

About Neurocrine Biosciences

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

2,500 employeesSan Diego, CAneurocrine.com

What Neurocrine Biosciences says it competes with

“We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.”

From its annual report, SEC filing · Feb 11, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on NBIX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move NBIX's score: 4 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

See NBIX's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: NBIX's Quality Score is 14 (Above Average), #23 of 281 in Biotech.

What does NBIX's Quality Score say?

NBIX scores 14 today, which Breakaway calls Above Average. It is #23 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 13.4% on Nov 3, and still 13% over its Nov 2 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NBIX's Quality Score?

NBIX scores 14 today, which Breakaway calls Above Average (11 to 14). That is #23 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NBIX's 14.

When does NBIX report earnings?

Expected to report Thu Feb 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. NBIX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.